{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:26:36Z","timestamp":1792509996159,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cognitive impairment in patients with schizophrenia is one of the symptoms most closely associated with functional loss throughout the disease course. There is increasing evidence suggesting that inflammation and nutritional status may contribute to impaired cognitive functions. The C-reactive protein\/albumin ratio (CRP\/ALB), prognostic nutritional index (PNI), and C-reactive protein\u2013albumin\u2013lymphocyte index (CALLY index) are easily calculated composite biomarkers reflecting nutritional status and immune-inflammatory processes. This study investigated the associations of the CRP\/ALB, PNI, and CALLY indices with cognitive impairment in patients with schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 131 individuals (88 schizophrenia patients and 43 healthy controls) were included. Cognitive assessment was performed via the Montreal Cognitive Assessment Scale (MoCA). On the basis of the MoCA, 26 patients had cognitive impairment (SCH-CI), and 62 were classified as schizophrenia patients with preserved cognitive function (SCH-R), and 43 constituted the healthy control (HC) group. Serum ALB, lymphocyte, and CRP levels were first measured. The CRP\/ALB ratio, PNI, and CALLY indices were then calculated on the basis of these parameters. Group differences were assessed via statistical analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The CRP\/ALB ratio was significantly higher in both schizophrenia groups than in the HC group (p2\u2009&lt;\u20090.001; p3\u2009&lt;\u20090.001), whereas no significant difference was observed between the SCH-CI and SCH-R groups (p1\u2009=\u20091.000). The CALLY index was significantly lower in both schizophrenia groups than in the HC group (p2\u2009&lt;\u20090.001; p3\u2009&lt;\u20090.001), with no significant unadjusted difference between SCH-CI and SCH-R (p1\u2009=\u20090.200). PNI values were significantly lower in the SCH-CI group than in both the SCH-R (p1\u2009=\u20090.008) and HC groups (p2\u2009=\u20090.013), whereas no significant difference was observed between the SCH-R and HC groups (p3\u2009=\u20091.000). In multivariable logistic regression analyses adjusted for age, sex, body mass index, smoking status, education year, depot antipsychotic use, and treatment duration, the CALLY index remained independently associated with cognitive impairment (OR\u2009=\u20090.112, 95% CI: 0.013\u20130.943,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044), whereas the association for PNI was attenuated to borderline significance (OR\u2009=\u20090.895, 95% CI: 0.800\u20131.001,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.052). The CRP\/ALB ratio was not independently associated with cognitive impairment (OR\u2009=\u200913.363, 95% CI: 0.147\u20131212.867,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.260).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cognitive impairment in schizophrenia may be associated with disturbances in inflammatory and immunonutritional status. Among the evaluated biomarkers, the CALLY index showed the most robust independent association with cognitive impairment after adjustment for relevant covariates, whereas the association for PNI was weaker. Although these markers are inexpensive and easily obtainable from routine laboratory parameters, their modest discriminatory performance suggests that they may be more useful as supportive or risk-stratification markers than as standalone diagnostic tools. Larger prospective studies are needed to validate their clinical utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-08021-0","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:35:36Z","timestamp":1774600536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The relationship between cognitive function and inflammatory-nutritional status in schizophrenia: cognitive impairment is inversely related to PNI and CALLY indices"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-4916","authenticated-orcid":false,"given":"Okan","family":"Imre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-9915","authenticated-orcid":false,"given":"Aysegul","family":"Kirkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"8021_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","volume":"264","author":"R Tandon","year":"2024","unstructured":"Tandon R, Nasrallah H, Akbarian S, et al. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophr Res. 2024;264:1\u201328. https:\/\/doi.org\/10.1016\/j.schres.2023.11.015.","journal-title":"Schizophr Res"},{"issue":"2","key":"8021_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry. 2020;77(2):201\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3360.","journal-title":"JAMA Psychiatry"},{"key":"8021_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S96649","volume":"12","author":"HY Chong","year":"2016","unstructured":"Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357\u201373. https:\/\/doi.org\/10.2147\/NDT.S96649. Published 2016 Feb 16.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"8021_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbt085","volume":"40","author":"E Bora","year":"2014","unstructured":"Bora E, Murray RM. Meta-analysis of cognitive deficits in ultrahigh risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014;40(4):744\u201355. https:\/\/doi.org\/10.1093\/schbul\/sbt085.","journal-title":"Schizophr Bull"},{"issue":"3","key":"8021_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","volume":"131","author":"RE Nielsen","year":"2015","unstructured":"Nielsen RE, Levander S, Kjaersdam Tell\u00e9us G, Jensen SO, \u00d8stergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2013a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185\u201396. https:\/\/doi.org\/10.1111\/acps.12374.","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 2","key":"8021_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4088\/JCP.14074su1c.02","volume":"77","author":"MF Green","year":"2016","unstructured":"Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry. 2016;77(Suppl 2):8\u201311. https:\/\/doi.org\/10.4088\/JCP.14074su1c.02.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"8021_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/jpm13091342","volume":"13","author":"O \u0130mre","year":"2023","unstructured":"\u0130mre O, Caglayan C, Mu\u015ftu M. The relationship of cognitive dysfunction with inflammatory markers and carotid intima media thickness in schizophrenia. J Pers Med. 2023;13(9):1342. https:\/\/doi.org\/10.3390\/jpm13091342. Published 2023 Aug 30.","journal-title":"J Pers Med"},{"issue":"3","key":"8021_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/ijms23031217","volume":"23","author":"A Morozova","year":"2022","unstructured":"Morozova A, Zorkina Y, Abramova O, et al. Neurobiological highlights of cognitive impairment in psychiatric disorders. Int J Mol Sci. 2022;23(3):1217. https:\/\/doi.org\/10.3390\/ijms23031217. Published 2022 Jan 22.","journal-title":"Int J Mol Sci"},{"key":"8021_CR9","doi-asserted-by":"publisher","unstructured":"M\u0142ynarska E, Jakubowska P, Fr\u0105k W, et al. Associations of microbiota and nutrition with cognitive impairment in diseases. Nutrients. 2024;16(20):3570. https:\/\/doi.org\/10.3390\/nu16203570. Published 2024 Oct 21.","DOI":"10.3390\/nu16203570"},{"issue":"7","key":"8021_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663\u201371. https:\/\/doi.org\/10.1016\/j.biopsych.2011.04.013.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"8021_CR11","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00406-024-01885-x","volume":"275","author":"Y Li","year":"2025","unstructured":"Li Y, Zhu M, Dong Y, et al. Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unravelling distinct patterns in clozapine-resistant patients. Eur Arch Psychiatry Clin Neurosci. 2025;275(5):1391\u2013401. https:\/\/doi.org\/10.1007\/s00406-024-01885-x.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"8021_CR12","doi-asserted-by":"publisher","first-page":"3467419","DOI":"10.1155\/2020\/3467419","volume":"2020","author":"YH Chen","year":"2020","unstructured":"Chen YH, Wang L, Feng SY, Cai WM, Chen XF, Huang ZM. The relationship between C-Reactive protein\/albumin ratio and disease activity in patients with inflammatory bowel disease. Gastroenterol Res Pract. 2020;2020:3467419. https:\/\/doi.org\/10.1155\/2020\/3467419. Published 2020 Jun 22.","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"8021_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0002-9610(80)90246-9","volume":"139","author":"GP Buzby","year":"1980","unstructured":"Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139(1):160\u20137. https:\/\/doi.org\/10.1016\/0002-9610(80)90246-9.","journal-title":"Am J Surg"},{"issue":"1","key":"8021_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.hpb.2021.06.414","volume":"24","author":"H Iida","year":"2022","unstructured":"Iida H, Tani M, Komeda K, et al. Superiority of CRP-albumin-lymphocyte index (CALLY index) as a noninvasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. HPB (Oxford). 2022;24(1):101\u201315. https:\/\/doi.org\/10.1016\/j.hpb.2021.06.414.","journal-title":"HPB (Oxford)"},{"issue":"9","key":"8021_CR15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.30773\/pi.2020.0185","volume":"17","author":"YH Balcioglu","year":"2020","unstructured":"Balcioglu YH, Kirlioglu SS. C-reactive protein\/albumin and neutrophil\/albumin ratios as novel inflammatory markers in patients with schizophrenia. Psychiatry Investig. 2020;17(9):902\u201310. https:\/\/doi.org\/10.30773\/pi.2020.0185.","journal-title":"Psychiatry Investig"},{"issue":"4","key":"8021_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"key":"8021_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.genhosppsych.2020.05.011","volume":"65","author":"EC Rosca","year":"2020","unstructured":"Rosca EC, Cornea A, Simu M. Montreal Cognitive Assessment for evaluating the cognitive impairment in patients with schizophrenia: a systematic review. Gen Hosp Psychiatry. 2020;65:64\u201373. https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.05.011.","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"8021_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.12740\/PP\/45368","volume":"50","author":"N Ciesielska","year":"2016","unstructured":"Ciesielska N, Soko\u0142owski R, Mazur E, Podhorecka M, Polak-Szabela A, K\u0119dziora-Kornatowska K. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Psychiatr Pol. 2016;50(5):1039\u201352. https:\/\/doi.org\/10.12740\/PP\/45368.","journal-title":"Psychiatr Pol"},{"issue":"7","key":"8021_CR19","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/jcm14072288","volume":"14","author":"O Imre","year":"2025","unstructured":"Imre O, Imre G, Mustu M, Acat O, Kocabas R. Cardiovascular disease markers in schizophrenia during negative symptoms and remission periods. J Clin Med. 2025;14(7):2288. https:\/\/doi.org\/10.3390\/jcm14072288. Published 2025 Mar 27.","journal-title":"J Clin Med"},{"key":"8021_CR20","doi-asserted-by":"publisher","unstructured":"Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https:\/\/doi.org\/10.3389\/fimmu.2018.00754. Published 2018 Apr 13.","DOI":"10.3389\/fimmu.2018.00754"},{"key":"8021_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fpsyt.2018.00392","volume":"9","author":"G Fond","year":"2018","unstructured":"Fond G, Lan\u00e7on C, Auquier P, Boyer L. C-Reactive protein as a peripheral biomarker in schizophrenia. An Updated Systematic Review. Front Psychiatry. 2018;9:392. https:\/\/doi.org\/10.3389\/fpsyt.2018.00392. Published 2018 Aug 23.","journal-title":"Front Psychiatry"},{"key":"8021_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.schres.2017.04.015","volume":"192","author":"B Misiak","year":"2018","unstructured":"Misiak B, Sta\u0144czykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res. 2018;192:16\u201329. https:\/\/doi.org\/10.1016\/j.schres.2017.04.015.","journal-title":"Schizophr Res"},{"issue":"6","key":"8021_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/antiox13060709","volume":"13","author":"NS Rawani","year":"2024","unstructured":"Rawani NS, Chan AW, Dursun SM, Baker GB. The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction. Antioxid (Basel). 2024;13(6):709. https:\/\/doi.org\/10.3390\/antiox13060709. Published 2024 Jun 12.","journal-title":"Antioxid (Basel)"},{"issue":"1","key":"8021_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/s40001-025-02925-5","volume":"30","author":"Y Li","year":"2025","unstructured":"Li Y, Chen L, Yang X, et al., et al. Dynamic association of serum albumin changes with inflammation, nutritional status and clinical outcomes: a secondary analysis of a large prospective observational cohort study. Eur J Med Res. 2025;30(1):679. https:\/\/doi.org\/10.1186\/s40001-025-02925-5. Published 2025 Jul 28.","journal-title":"Eur J Med Res"},{"issue":"28","key":"8021_CR25","doi-asserted-by":"publisher","first-page":"8295","DOI":"10.12998\/wjcc.v9.i28.8295","volume":"9","author":"OJ Onaolapo","year":"2021","unstructured":"Onaolapo OJ, Onaolapo AY. Nutrition, nutritional deficiencies, and schizophrenia: An association worthy of constant reassessment. World J Clin Cases. 2021;9(28):8295\u2013311. https:\/\/doi.org\/10.12998\/wjcc.v9.i28.8295.","journal-title":"World J Clin Cases"},{"issue":"1","key":"8021_CR26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12888-024-06335-5","volume":"24","author":"D Li","year":"2024","unstructured":"Li D, Huang Y, Lu H, et al. Association between cognitive function, antioxidants, and clinical variables in Chinese patients with schizophrenia. BMC Psychiatry. 2024;24(1):912. https:\/\/doi.org\/10.1186\/s12888-024-06335-5. Published 2024 Dec 18.","journal-title":"BMC Psychiatry"},{"issue":"2\u20133","key":"8021_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0165-1781(00)00230-4","volume":"97","author":"JK Yao","year":"2000","unstructured":"Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 2000;97(2\u20133):137\u201351. https:\/\/doi.org\/10.1016\/s0165-1781(00)00230-4.","journal-title":"Psychiatry Res"},{"key":"8021_CR28","doi-asserted-by":"publisher","first-page":"957671","DOI":"10.3389\/fpsyt.2022.957671","volume":"13","author":"XY Yin","year":"2022","unstructured":"Yin XY, Cai Y, Zhu ZH, et al. Associations of decreased serum total protein, albumin, and globulin with depressive severity of schizophrenia. Front Psychiatry. 2022;13:957671. https:\/\/doi.org\/10.3389\/fpsyt.2022.957671. Published 2022 Jul 25.","journal-title":"Front Psychiatry"},{"key":"8021_CR29","doi-asserted-by":"publisher","first-page":"1599830","DOI":"10.3389\/fnut.2025.1599830","volume":"12","author":"H Ding","year":"2025","unstructured":"Ding H, Zou X. Association of prognostic nutritional index with all-cause and cardiovascular mortality in adults with depression: NHANES 2005\u20132018. Front Nutr. 2025;12:1599830. https:\/\/doi.org\/10.3389\/fnut.2025.1599830. Published 2025 May 19.","journal-title":"Front Nutr"},{"issue":"1","key":"8021_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12889-024-17925-z","volume":"24","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang L, Yang Q, et al. Association between geriatric nutritional risk index and depression prevalence in the elderly population in NHANES. BMC Public Health. 2024;24(1):469. https:\/\/doi.org\/10.1186\/s12889-024-17925-z. Published 2024 Feb 14.","journal-title":"BMC Public Health"},{"key":"8021_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.schres.2017.04.011","volume":"192","author":"MT Tsai","year":"2018","unstructured":"Tsai MT, Chang TH, Wu BJ. Prognostic impact of nutritional risk assessment in patients with chronic schizophrenia. Schizophr Res. 2018;192:137\u201341. https:\/\/doi.org\/10.1016\/j.schres.2017.04.011.","journal-title":"Schizophr Res"},{"key":"8021_CR32","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.2147\/NDT.S423399","volume":"19","author":"H Xu","year":"2023","unstructured":"Xu H, Zheng L, Wang L, Gao H, Wei Y, Chen J. Albumin and Associated biomarkers in severe neuropsychiatric disorders: acute-phase schizophrenia and bipolar disorder. Neuropsychiatr Dis Treat. 2023;19:2027\u201337. https:\/\/doi.org\/10.2147\/NDT.S423399. Published 2023 Sep 28.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"8021_CR33","doi-asserted-by":"publisher","first-page":"e0312227","DOI":"10.1371\/journal.pone.0312227","volume":"19","author":"B Wang","year":"2024","unstructured":"Wang B, Zhou Y, Yu H, et al. Correlations between nutritional indicators and cognitive function in patients with stable schizophrenia in a hospital setting. PLoS ONE. 2024;19(11):e0312227. https:\/\/doi.org\/10.1371\/journal.pone.0312227. Published 2024 Nov 4.","journal-title":"PLoS ONE"},{"issue":"4","key":"8021_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/00912174241266059","volume":"60","author":"A Karahan","year":"2025","unstructured":"Karahan A, Manzak Saka I, Sa\u011flam Aykut D, Civil Arslan F, Sel\u00e7uk \u00d6zmen E. \u00d6zkorumak Karag\u00fczel E. Peripheral immune cell markers and cognitive function in patients with schizophrenia. Int J Psychiatry Med. 2025;60(4):405\u201319. https:\/\/doi.org\/10.1177\/00912174241266059.","journal-title":"Int J Psychiatry Med"},{"key":"8021_CR35","doi-asserted-by":"publisher","first-page":"1498478","DOI":"10.3389\/fnagi.2025.1498478","volume":"17","author":"CY Lin","year":"2025","unstructured":"Lin CY, Zhai YJ, Wu F, et al. Interaction and overall effects of underweight, low muscle mass, malnutrition, and inflammation on early-onset mild cognitive impairment in type 2 diabetes. Front Aging Neurosci. 2025;17:1498478. https:\/\/doi.org\/10.3389\/fnagi.2025.1498478. Published 2025 Mar 27.","journal-title":"Front Aging Neurosci"},{"key":"8021_CR36","doi-asserted-by":"publisher","first-page":"110668","DOI":"10.1016\/j.pnpbp.2022.110668","volume":"121","author":"SR Patlola","year":"2023","unstructured":"Patlola SR, Donohoe G, McKernan DP. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023;121:110668. https:\/\/doi.org\/10.1016\/j.pnpbp.2022.110668.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"8021_CR37","doi-asserted-by":"publisher","first-page":"1458184","DOI":"10.3389\/fneur.2024.1458184","volume":"15","author":"Y Cui","year":"2024","unstructured":"Cui Y, Li C, Ke B, et al. Protective role of serum albumin in dementia: a prospective study from United Kingdom biobank. Front Neurol. 2024;15:1458184. https:\/\/doi.org\/10.3389\/fneur.2024.1458184. Published 2024 Aug 14.","journal-title":"Front Neurol"},{"issue":"1","key":"8021_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/10398562211022753","volume":"30","author":"X Zhu","year":"2022","unstructured":"Zhu X, Zhou J, Zhu Y, et al. Neutrophil\/lymphocyte, platelet\/lymphocyte and monocyte\/lymphocyte ratios in schizophrenia. Australas Psychiatry. 2022;30(1):95\u20139. https:\/\/doi.org\/10.1177\/10398562211022753.","journal-title":"Australas Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08021-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:25Z","timestamp":1781643565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08021-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8021"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08021-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Karamano\u011flu Mehmetbey University, Faculty of Medicine (Approval Number: 23-2025\/17). All procedures involving human participants were conducted in accordance with the 2013 Declaration of Helsinki. Written informed consent was obtained from all participants, who were informed about the study procedures and assured of their right to withdraw at any time without providing a reason.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}